Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC

by Zacks Equity Research Published on February 03,2017

Bristol-Myers Squibb Company (BMY) announced that the FDA has approved an injectable form of immuno-oncology drug Opdivo

• RHHBY Quick QuoteRHHBYPositive Net Change
• BMY Quick QuoteBMYPositive Net Change
• LLY Quick QuoteLLYNegative Net Change

Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales

by Zacks Equity Research Published on February 02,2017

Roche beat on earnings but missed on sales in 2016 due to decline in sales of Lucentis, Pegasys, Avastin and Tarceva.

• RHHBY Quick QuoteRHHBYPositive Net Change
• BMY Quick QuoteBMYPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• ABBV Quick QuoteABBVPositive Net Change

SanofiRegeneron Sarilumab Approved in Canada for Arthritis

by Zacks Equity Research Published on February 01,2017

Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).

• RHHBY Quick QuoteRHHBYPositive Net Change
• SNY Quick QuoteSNYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• REGN Quick QuoteREGNPositive Net Change

Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug

by Zacks Equity Research Published on January 30,2017

Pfizer Inc. (PFE) announced that Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company's marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz.

• RHHBY Quick QuoteRHHBYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Roche (RHHBY) Arthritis Drug Actemra sBLA Accepted by FDA

by Zacks Equity Research Published on January 25,2017

Roche's (RHHBY) supplemental Biologics License Application (sBLA) for arthritis drug, Actemra, accepted for review by the FDA for giant cell arteritis (GCA).

• RHHBY Quick QuoteRHHBYPositive Net Change
• ENZ Quick QuoteENZPositive Net Change
• SCMP Quick QuoteSCMPPositive Net Change
• SNSS Quick QuoteSNSSPositive Net Change

BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda

by Zacks Equity Research Published on January 19,2017

BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.

• RHHBY Quick QuoteRHHBYPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• NVLS Quick QuoteNVLSPositive Net Change
• BLRX Quick QuoteBLRXPositive Net Change

Merck KGaA Expands Distribution Deal with Roche (revised)

by Zacks Equity Research Published on January 17,2017

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

• RHHBY Quick QuoteRHHBYPositive Net Change
• CBM Quick QuoteCBMPositive Net Change
• VNDA Quick QuoteVNDAPositive Net Change

Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News

by Arpita Dutt Published on January 13,2017

The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.

• RHHBY Quick QuoteRHHBYPositive Net Change
• BMY Quick QuoteBMYPositive Net Change
• LLY Quick QuoteLLYNegative Net Change

Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.

by Zacks Equity Research Published on January 12,2017

Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.

• RHHBY Quick QuoteRHHBYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• SCMP Quick QuoteSCMPPositive Net Change

by Zacks Equity Research Published on January 10,2017

• CLVS Quick QuoteCLVSPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• RHHBY Quick QuoteRHHBYPositive Net Change

Roche Gets Priority Review for Immunotherapy Drug Tecentriq

by Zacks Equity Research Published on January 10,2017

Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.

• RHHBY Quick QuoteRHHBYPositive Net Change
• BMY Quick QuoteBMYPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• SCMP Quick QuoteSCMPPositive Net Change

The FDA Approved Fewer Drugs in 2016: Here's Why

by Arpita Dutt Published on January 09,2017

Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

• RHHBY Quick QuoteRHHBYPositive Net Change
• SNY Quick QuoteSNYPositive Net Change
• AZN Quick QuoteAZNPositive Net Change

Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication

by Zacks Equity Research Published on January 06,2017

Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.

• RHHBY Quick QuoteRHHBYPositive Net Change
• NVS Quick QuoteNVSPositive Net Change
• REGN Quick QuoteREGNPositive Net Change

Mylan/Biocon's Herceptin Biosimilar Phase III Data Published

by Zacks Equity Research Published on December 28,2016

Mylan (MYL) and partner Biocon's biosimilar version of Herceptin phase III data published in JAMA.

• RHHBY Quick QuoteRHHBYPositive Net Change
• MNTA Quick QuoteMNTAPositive Net Change
• MYL Quick QuoteMYLPositive Net Change
• ADMS Quick QuoteADMSPositive Net Change

Roche (RHHBY) Hemophilia A Drug Positive in Phase III

by Zacks Equity Research Published on December 23,2016

Roche (RHHBY) announced that the phase III study, HAVEN 1, met its primary endpoint.

• RHHBY Quick QuoteRHHBYPositive Net Change
• HSKA Quick QuoteHSKAPositive Net Change
• VNDA Quick QuoteVNDAPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe

by Arpita Dutt Published on December 23,2016

J&J (JNJ) and Actelion are back in the limelight with the companies in exclusive talks regarding a possible deal.

• RHHBY Quick QuoteRHHBYPositive Net Change
• BMY Quick QuoteBMYPositive Net Change
• AGN Quick QuoteAGNPositive Net Change

Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx

by Zacks Equity Research Published on December 22,2016

Exelixis, Inc. (EXEL) announced that it has amended the exclusive collaboration and licensing agreement with its European partner Ipsen.

• RHHBY Quick QuoteRHHBYPositive Net Change
• EXEL Quick QuoteEXELPositive Net Change
• HSKA Quick QuoteHSKAPositive Net Change
• VNDA Quick QuoteVNDAPositive Net Change

Merrimack (MACK) Drops as Breast Cancer Drug Trial Stops

by Zacks Equity Research Published on December 22,2016

Shares of Merrimack Pharmaceuticals, Inc. (MACK) tanked 18.4% after the company announced the discontinuation of a phase II trial on its breast cancer candidate, MM-302.

• RHHBY Quick QuoteRHHBYPositive Net Change
• HSKA Quick QuoteHSKAPositive Net Change
• VNDA Quick QuoteVNDAPositive Net Change
• MACK Quick QuoteMACKPositive Net Change

Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU

by Zacks Equity Research Published on December 21,2016

Pfizer Inc. (PFE) announced that the European Commission has approved an expanded indication for its meningococcal vaccine, Nimenrix.

• RHHBY Quick QuoteRHHBYPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• HSKA Quick QuoteHSKAPositive Net Change
• VNDA Quick QuoteVNDAPositive Net Change

Roche (RHHBY) MS Drug FDA Review Date Extended in U.S.

by Zacks Equity Research Published on December 21,2016

Roche (RHHBY) announced that the FDA has extended the PDUFA date for the review of the company's Biologics License Application (BLA) for Ocrevus.

• RHHBY Quick QuoteRHHBYPositive Net Change

Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

by Zacks Equity Research Published on December 16,2016

Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

• RHHBY Quick QuoteRHHBYPositive Net Change
• VNDA Quick QuoteVNDAPositive Net Change
• SCMP Quick QuoteSCMPPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Merck (MRK) Offers Update on Keytruda-Halaven Combination

by Zacks Equity Research Published on December 13,2016

Merck (MRK) and Eisai (ESALY) announced new interim data from a phase Ib/II study on the Keytruda-Halaven combination for the treatment of metastatic TNBC.

• RHHBY Quick QuoteRHHBYPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• HSKA Quick QuoteHSKAPositive Net Change
• ESALY Quick QuoteESALYPositive Net Change

Ophthotech Hits 52-Week Low on Unfavorable Fovista Data

by Zacks Equity Research Published on December 13,2016

Ophthotech's (OPHT) shares tumbled 86.4% to a 52-week low after the company reported disappointing phase III data on its eye drug, Fovista, in wet AMD patients.

• RHHBY Quick QuoteRHHBYPositive Net Change
• NVS Quick QuoteNVSPositive Net Change
• REGN Quick QuoteREGNPositive Net Change
• OPHT Quick QuoteOPHTNo Net Change

Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

by Zacks Equity Research Published on December 12,2016

Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

• RHHBY Quick QuoteRHHBYPositive Net Change
• VNDA Quick QuoteVNDAPositive Net Change
• SCMP Quick QuoteSCMPPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Biogen Presents Positive Early Data from Alzheimer's Study

by Zacks Equity Research Published on December 12,2016

Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.

• RHHBY Quick QuoteRHHBYPositive Net Change
• AZN Quick QuoteAZNPositive Net Change
• LLY Quick QuoteLLYNegative Net Change
• BIIB Quick QuoteBIIBPositive Net Change